دورية أكاديمية
Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
| العنوان: | Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials. |
|---|---|
| المؤلفون: | Simpson, Eric L., Merola, Joseph F., Silverberg, Jonathan I., Reich, Kristian, Warren, Richard B., Staumont, Delphine, Girolomoni, Giampiero, Papp, Kim, de Bruin-Weller, Marjolein, Thyssen, Jacob P., Zachariae, Rebecca, Olsen, Christiana K., Wollenberg, Andreas |
| المساهمون: | Oregon Health and Science University Portland (OHSU), The George Washington University (GW), NIHR Biomedical Research Centre London, Guy's and St Thomas' NHS Foundation Trust-King‘s College London, Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Università degli studi di Verona = University of Verona (UNIVR), University Medical Center Utrecht, University of Copenhagen = Københavns Universitet (UCPH), Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU) |
| المصدر: | ISSN: 1365-2133 ; The British journal of dermatology ; https://hal.univ-lille.fr/hal-04428303Test ; The British journal of dermatology, 2022, British Journal of Dermatology, 187, pp.888-899. ⟨10.1111/bjd.21867⟩. |
| بيانات النشر: | HAL CCSD |
| سنة النشر: | 2022 |
| المجموعة: | LillOA (HAL Lille Open Archive, Université de Lille) |
| مصطلحات موضوعية: | [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Tralokinumab, an anti‐interleukin‐13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical trials and was well tolerated, with a safety profile comparable to placebo. This study comprehensively assessed the safety profile of tralokinumab using data from five placebo‐controlled trials in adult patients with moderate‐to‐severe AD, finding that overall incidence and rate of adverse events (AEs) was similar between tralokinumab and placebo in the initial treatment period (16 weeks) and did not increase over 52 weeks of continued treatment. Common AEs occurring more frequently with tralokinumab included conjunctivitis and injection site reaction. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36082590; hal-04428303; https://hal.univ-lille.fr/hal-04428303Test; https://hal.univ-lille.fr/hal-04428303/documentTest; https://hal.univ-lille.fr/hal-04428303/file/bjd0888.pdfTest; PUBMED: 36082590 |
| DOI: | 10.1111/bjd.21867 |
| الإتاحة: | https://doi.org/10.1111/bjd.21867Test https://hal.univ-lille.fr/hal-04428303Test https://hal.univ-lille.fr/hal-04428303/documentTest https://hal.univ-lille.fr/hal-04428303/file/bjd0888.pdfTest |
| حقوق: | http://creativecommons.org/licenses/by-ncTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.98B2EB83 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/bjd.21867 |
|---|